Nektar Therapeutics (NKTR) entered a quiet period beginning this month as it awaits the trial results for its lead drug candidate, Rezpegaldesleukin, in alopecia areata.
Rezpegaldesleukin, also known as Rezpeg, NKTR-358, or formerly LY3471851, is a pegylated recombinant human interleukin-2 (IL-2) therapeutic. This engineered biologic is a modified form of a naturally occurring protein that plays a key role in regulating immune system activity.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.